FDA Approves Pill That Nearly Doubled Median Survival In Pancreatic Cancer Trial

FDA Approves Pill That Nearly Doubled Median Survival In Pancreatic Cancer Trial
dallasexpress.com

FDA Approves Pill That Nearly Doubled Median Survival In Pancreatic Cancer Trial

The FDA approved Rasonque on Aug 26 for metastatic pancreatic cancer. The pill nearly doubled median survival versus chemotherapy.